Michael Hamacher is CEO of Affectis Pharmaceuticals AG since 2014 as well as Head of Finance & Human Resources at Lead Discovery Center GmbH (LDC), both located in Dortmund, Germany. At LDC, he is responsible for Finances, HR, Business Development and Funding. Before moving to the LDC in the company´s founding year 2008, he was at the Medizinisches Proteom-Center of the Ruhr-Universität Bochum, Germany, implementing the Human Brain Proteome Project (HBPP) in the Human Proteome Organisation (HUPO) among others. Thus, he has extensive experience in applying and managing (publicly funded) projects as well as in building-up new company structures. Michael made his PhD in Biology in 2003 and is (co-)author of more than 35 peer-reviewed articles and editor of three books.
Klaus Dinkel is the Affectis project manager of LDC GmbH. He is an immunobiologist with over 10 years experience in the pharmaceutical industry as project leader, project manager and group leader in drug research and development. Before moving to the LDC in 2010, he was working for Jerini AG (Berlin) and the CRO FAN (Magdeburg). Between 2002 and 2005 Klaus worked as post-doctoral researcher at Stanford University, California. He received his Ph.D. in Human Biology (Immunology) awarded with “summa cum laude” from the University of Ulm, Germany and authored >20 peer-reviewed publications in high impact journals (e.g. PNAS, Nature Neuroscience, FASEB) in the field of inflammation and CNS immunology.
Affectis is heading for the development of novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Affectis is working closely together with the Lead Discovery Center GmbH to further advance its core asset AFC-5128, a potent and specific, brain-permeable P2X7R antagonist for the treatment of a variety of disorders (Epilepsy, MS, pain among others).
About Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Affectis’ capabilities in drug discovery and medicinal chemistry allowed the company to develop drugs with innovative mechanisms of action based on pioneering findings in the field of P2X7 receptors.
Affectis started operations in January 2004 as a spin-off from the Max Planck Institute of Psychiatry. The company’s founders include Florian Holsboer, a key opinion leader in psychiatry, Wolfgang Wurst, an expert in mouse genetics, and Herbert Stadler, a serial biotech entrepreneur.
Since January 2014 Affectis has relocated to Dortmund, Germany, and is now fully owned by and closely collaborating with the Lead Discovery Center GmbH (LDC) to further advance its core asset AFC-5128.